FDA approves add-on to controversial surgical device
The U.S. Food and Drug Administration on Thursday announced the approval of the first tissue-containment bag for use with a gynecological surgical device that can spread undetected cancer.
The U.S. Food and Drug Administration on Thursday announced the approval of the first tissue-containment bag for use with a gynecological surgical device that can spread undetected cancer.
At the same time, the agency continued to warn that the tissue-slicing surgical device, called a power morcellator, should not be used in most cases. And the FDA further warned that the new bag "has not been proved to reduce the risk of spreading cancer."
The FDA estimates that about 1 in 350 women who undergo hysterectomy or uterine fibroid removal will have an unsuspected sarcoma, an aggressive uterine cancer. If the surgery is done with a power morcellator, the procedure can spread the cancer and worsen the patient's prognosis.
The FDA was unaware of that danger until late 2013, when anesthesiologist Amy Reed and her husband, cardiac surgeon Hooman Noorchashm, began campaigning to ban electric morcellators. Reed's undetected sarcoma was spread by the device during a hysterectomy at Brigham & Women's Hospital in Boston.
The couple and their six children now live in the Philadelphia area, where she is battling the metastatic cancer.
The newly approved containment bag, called PneumoLiner, is intended to provide an enclosed working space for the morcellator inside the woman's abdominal cavity, enabling capture and removal of all morcellated tissue. In laboratory tests, the bag did not leak cells or body fluids, and it withstood the pulling and other forces expected to occur during actual use.
Noorchashm denounced the approval of the bag as "astonishing" and irresponsible, given that the FDA has not changed its position that power morcellation poses serious risks.
Introduced in 1993, electric morcellators have motorized blades that dissect tissue so it can be removed through tiny abdominal incisions. Patients recover faster than with the traditional cut-open-the-abdomen hysterectomy. About 50,000 hysterectomies a year involved the device before the controversy erupted a couple of years ago, sharply lessening its use.
The FDA now says it should be used only in relatively rare cases, such as some pre-menopausal women who want to get rid of fibroids but preserve their fertility by leaving the uterus intact.
"PneumoLiner is intended to contain morcellated tissue in the very limited patient population for whom power morcellation may be an appropriate therapeutic option - and only if patients have been appropriately informed of the risks," FDA deputy director William Maisel said in a news release.
PneumoLiner is made by Advanced Surgical Concepts Ltd. of Bray, Ireland. The FDA said the product was reviewed under regulations for "low- to moderate-risk devices that are first-of-a-kind."
The labeling for PneumoLiner will include a prominent warning that "the use of this containment system has not been clinically demonstrated to reduce the risk" of spreading an unsuspected uterine cancer.
215-854-2720
@repopter























